Two-year follow-up data from the RELATIVITY-047 trial (NCT03470922) showed a continued benefit for patients with previously untreated, unresectable, or metastatic melanoma receiving nivolumab plus relatlimab (Opdualag) vs nivolumab (Opdivo) monotherapy supporting the use of the combination, according to Hussein A. Tawbi, MD, PhD.
Clinical Trials
Nasal Administration of Novel Recombinant Protozoan Strain Prevents Metastatic Melanoma in the Lung
The protozoan intranasal treatment was associated with a strong increase of immune cells within the lung.
Nivolumab/Relatlimab Shows PFS/OS Benefit Over Nivolumab in Melanoma
Targeted Oncology: What data support the combination of nivolumab and relatlimab (Opdualag) for patients with metastatic melanoma?
Darovasertib Plus Crizotinib Shows Early Promise in Metastatic Uveal Melanoma
The combination of darovasertib (IDE196) and crizotinib (Xalkori) demonstrated clinical activity and an acceptable safety profile when utilized in first- and any-line patients with metastatic uveal melanoma, according to interim results from a phase 2 trial (NCT03947385).